创伤后压力症候群治疗市场－全球产业规模、份额、趋势、机会和预测：按药物类别、分销管道、地区和竞争格局划分，2021-2031年

全球创伤后压力症候群 (PTSD) 治疗市场预计将从 2025 年的 9.6939 亿美元成长到 2031 年的 12.8063 亿美元，预测期内复合年增长率为 4.75%。

治疗方法通常采用药物治疗和心理治疗相结合的方法，旨在缓解创伤经历引发的过度警觉、逃避行为和侵入性思维等症状。这个市场的主要驱动力是地缘政治衝突、自然灾害和事故造成的创伤事件日益增多，以及诊断工具的进步使得早期疗育可能。此外，政府加大对精神卫生基础设施的投入，以及公众对心理创伤长期影响的认识不断提高，也有效地扩大了积极寻求专业帮助的患者群体。

然而，合格的心理健康专业人员短缺以及专业治疗的高昂费用阻碍了市场成长，限制了患者获得持续治疗的机会。鑑于该疾病的慢性特征和长期管理的必要性，这种治疗机会的不平等尤为严重。世界卫生组织（世卫组织）预测，到2024年，全球约有3.9%的人口在其一生中的某个阶段会经历创伤后压力症候群（PTSD），这凸显了有效治疗方案在应对这一普遍存在的疾病负担方面存在着巨大的未满足需求。

市场驱动因素

新型药物和迷幻疗法的快速发展正在从根本上改变全球创伤后压力症候群（PTSD）治疗市场，克服了传统抗忧郁症的限制。临床开发平臺日益聚焦于迷幻剂辅助心理疗法，尤其是使用MDMA和裸盖菇素的疗法，为对标准疗法无效的患者提供了新的作用机制。这一趋势正推动大量资本投资，以推动这些化合物从临床试验走向商业化。例如，2024年1月，Lycos Therapeutics公司在A轮资金筹措中筹集了超过1亿美元，用于推进其MDMA辅助疗法的研究阶段。如此庞大的资金筹措反映了业界对下一代疗法的信心，这些治疗方法与传统药物干预相比，能够提供更优的症状缓解和功能恢復。

同时，对退伍军人復健和军人医疗保健支出的日益重视也在推动市场发展，因为世界各国政府都在优先考虑为军人提供心理健康资源。军人中较高的发病率要求为自杀预防和专门治疗计画提供充足的资金筹措，并确保对治疗服务的稳定需求。 2024年3月，美国退伍军人事务部申请在2025财政年度心理健康预算中拨款171亿美元，以改善医疗保健服务的可近性和品质。这项财政承诺至关重要。正如科恩退伍军人网络在2024年6月指出的那样，大约7%的退伍军人在其一生中的某个阶段会患上这种疾病，而美国成年人口的这一比例为6%，这使得联邦政府的此类支出成为持续采购医疗保健系统和解决方案的重要驱动力。

市场挑战

全球创伤后压力症候群（PTSD）治疗市场扩张的一大障碍是合格心理健康专业的短缺。这种短缺造成了严重的瓶颈，使医疗保健系统无法充分满足日益增长的创伤相关护理需求。当患者无法预约到合适的专家时，诊断率就会下降，必要的药物和心理治疗也会被延迟。因此，治疗服务和药物的使用量减少，儘管疾病的盛行率很高，但直接限制了相关人员的获利能力。

这种供需失衡严重限制了患者持续治疗的机会。根据美国心理学会预测，到2024年，约有53%的心理学家将表示没有空余名额接收新患者。如此严重的预约名额短缺迫使许多人放弃寻求专业协助，导致他们退出病患群体。这种对劳动力能力的结构性限制削弱了应对该疾病普遍负担的努力，并减缓了市场的整体成长势头。

市场趋势

将虚拟实境（VR）技术融入长期暴露疗法，透过提供一个可控的身临其境型创伤处理环境，正在革新迴避行为的管理方式。与传统的想像暴露疗法不同，VR平台允许临床医生重现创伤情境，并呈现特定的感官细节，从而帮助那些难以进行视觉想像的患者建立情感联繫并逐渐适应。这项技术正在联邦医疗保健系统中迅速扩展，以改善对军人的治疗服务。例如，2024年7月，美国退伍军人事务部报告称，已向170多家医疗中心部署了3500多台虚拟实境头戴设备，以支持退伍军人的康復和心理健康护理。

人工智慧驱动的数位疗法和心理健康应用程式的兴起，正在建立一种全新的、便利的、非侵入性的护理模式，作为传统药物疗法的补充。这些数位介入措施利用复杂的演算法和神经回馈机制，帮助调节患者的生理压力指标，为那些对传统药物疗法无效的患者提供了有效的替代方案。 FDA批准的、能够调节大脑活动的设备的商业性扩张，也印证了这一趋势。据GrayMatters Health公司称，其数位疗法「Prism」于2024年10月进行的一项关键临床试验显示，67%的参与者症状得到了显着改善。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：创伤后压力症候群治疗的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 药物分类（抗忧郁症、抗精神病药、抗焦虑药、其他）
  • 通路（医院药房、零售药房、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美创伤后压力症候群治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲创伤后压力症候群治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区创伤后压力症候群治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲创伤后压力症候群治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲创伤后压力症候群治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球创伤后压力症候群治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Lupin Limited
• Pfizer Inc.
• Aurobindo Pharma Limited
• Merck KGaA
• GlaxoSmithKline Plc
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Jazz Pharmaceuticals Inc.
• Bionomics Limited
• Aptinyx Inc.
• AstraZeneca Plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Post-traumatic Stress Disorder Treatment Market is projected to expand from USD 969.39 Million in 2025 to USD 1280.63 Million by 2031, registering a CAGR of 4.75% during the forecast period. Treatment regimens typically combine pharmacotherapy and psychotherapeutic approaches designed to mitigate symptoms such as hyperarousal, avoidance behaviors, and intrusive thoughts caused by traumatic experiences. The market is largely sustained by the growing incidence of trauma resulting from geopolitical conflicts, natural disasters, and accidents, alongside advancements in diagnostic tools that allow for earlier intervention. Furthermore, increased government investment in mental health infrastructure and rising public awareness regarding the long-term effects of psychological trauma are effectively broadening the patient population actively seeking professional help.

However, market growth is hindered by a scarcity of qualified mental health professionals and the high costs associated with specialized therapy, which restrict consistent patient access to care. This gap in accessibility is particularly critical given the chronic nature of the condition and the need for long-term management. According to the World Health Organization, approximately 3.9% of the global population in 2024 has experienced post-traumatic stress disorder at some point in their lives, highlighting a significant unmet need for effective therapeutic solutions to address this widespread burden.

Market Driver

The rapid advancement of novel pharmacotherapies and psychedelics is fundamentally transforming the global post-traumatic stress disorder treatment market by addressing the shortcomings of traditional antidepressants. Clinical pipelines are increasingly focusing on psychedelic-assisted psychotherapies, specifically using MDMA and psilocybin, which provide new mechanisms of action for patients resistant to standard treatments. This trend is attracting substantial capital investment to move these compounds from clinical trials to commercialization; for example, Lykos Therapeutics raised over $100 million in Series A funding in January 2024 to advance its investigational MDMA-assisted therapy. Such significant funding reflects the industry's confidence in these next-generation treatments to deliver better symptom remission and functional recovery than conventional pharmacologic interventions.

Simultaneously, the market is driven by a heightened focus on veteran rehabilitation and military healthcare spending, as governments prioritize mental health resources for service members. High prevalence rates among military personnel require robust funding for suicide prevention and specialized treatment programs, ensuring a steady demand for therapeutic services. In March 2024, the U.S. Department of Veterans Affairs requested $17.1 billion for its 2025 mental health budget to enhance access and quality of care. This financial commitment is crucial, as the Cohen Veterans Network noted in June 2024 that approximately 7% of veterans will experience the disorder in their lifetime, compared to 6% of the general U.S. adult population, making these federal expenditures a key catalyst for the consistent procurement of care systems and solutions.

Market Challenge

A primary obstacle to the expansion of the Global Post-traumatic Stress Disorder Treatment Market is the shortage of qualified mental health professionals. This workforce scarcity creates a critical bottleneck, preventing the healthcare system from adequately meeting the growing demand for trauma-related care. When patients struggle to secure timely appointments with specialists, diagnosis rates slow down, and the initiation of necessary pharmacotherapy or psychotherapy is delayed. As a result, the market sees reduced consumption of treatment services and medications, which directly limits revenue potential for industry stakeholders despite the high prevalence of the condition.

This imbalance between supply and demand significantly restricts patient access to consistent management. According to the American Psychological Association, roughly 53% of psychologists reported having no openings for new patients in 2024. This profound lack of availability compels many individuals to abandon their search for professional help, effectively removing them from the active patient pool. Such structural limitations in workforce capacity undermine efforts to address the widespread burden of the disorder, thereby slowing the overall growth trajectory of the market.

Market Trends

The incorporation of Virtual Reality into Prolonged Exposure Therapy is revolutionizing the management of avoidance behaviors by offering controlled, immersive environments for processing trauma. Unlike traditional imaginal exposure, virtual reality platforms allow clinicians to replicate traumatic scenarios with specific sensory details, facilitating emotional engagement and habituation in patients who find visualization difficult. This technology is being rapidly scaled within federal healthcare systems to improve therapeutic delivery for service members; for instance, the U.S. Department of Veterans Affairs reported in July 2024 that it had deployed over 3,500 virtual reality headsets across more than 170 medical centers to support veteran rehabilitation and mental health care.

The rise of AI-powered digital therapeutics and mental health apps is establishing a new paradigm of accessible, non-invasive care that serves as an adjunct to standard pharmacotherapy. These digital interventions employ advanced algorithms and neurofeedback mechanisms to help patients regulate physiological stress markers, offering a viable alternative for individuals resistant to conventional medication. This trend is illustrated by the commercial expansion of FDA-cleared devices designed to modulate brain activity; according to GrayMatters Health in October 2024, a pivotal clinical trial for its Prism digital therapeutic showed that 67% of participants achieved significant improvement in their symptoms.

Key Market Players

• Lupin Limited
• Pfizer Inc.
• Aurobindo Pharma Limited
• Merck KGaA
• GlaxoSmithKline Plc
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Jazz Pharmaceuticals Inc.
• Bionomics Limited
• Aptinyx Inc.
• AstraZeneca Plc

Report Scope

In this report, the Global Post-traumatic Stress Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Post-traumatic Stress Disorder Treatment Market, By Drug Class

• Antidepressants
• Antipsychotics
• Anti-anxiety
• Others

Post-traumatic Stress Disorder Treatment Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Post-traumatic Stress Disorder Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Post-traumatic Stress Disorder Treatment Market.

Available Customizations:

Global Post-traumatic Stress Disorder Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Post-traumatic Stress Disorder Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Antidepressants, Antipsychotics, Anti-anxiety, Others)
  • 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Post-traumatic Stress Disorder Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Post-traumatic Stress Disorder Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Post-traumatic Stress Disorder Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Post-traumatic Stress Disorder Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel

7. Europe Post-traumatic Stress Disorder Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Post-traumatic Stress Disorder Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. France Post-traumatic Stress Disorder Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Post-traumatic Stress Disorder Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Post-traumatic Stress Disorder Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Post-traumatic Stress Disorder Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Post-traumatic Stress Disorder Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Post-traumatic Stress Disorder Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Post-traumatic Stress Disorder Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Post-traumatic Stress Disorder Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Post-traumatic Stress Disorder Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Post-traumatic Stress Disorder Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Post-traumatic Stress Disorder Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Post-traumatic Stress Disorder Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. UAE Post-traumatic Stress Disorder Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. South Africa Post-traumatic Stress Disorder Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel

10. South America Post-traumatic Stress Disorder Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Post-traumatic Stress Disorder Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Colombia Post-traumatic Stress Disorder Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. Argentina Post-traumatic Stress Disorder Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Post-traumatic Stress Disorder Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Lupin Limited
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Aurobindo Pharma Limited
• 15.4. Merck KGaA
• 15.5. GlaxoSmithKline Plc
• 15.6. Otsuka Pharmaceutical Development & Commercialization, Inc.
• 15.7. Jazz Pharmaceuticals Inc.
• 15.8. Bionomics Limited
• 15.9. Aptinyx Inc.
• 15.10. AstraZeneca Plc

16. Strategic Recommendations

17. About Us & Disclaimer